Bank of Ireland Kernel Capital Growth Fund (NI) portfolio company, Cirdan has secured a Contract with the Australian Centre for the Prevention of Cervical Cancer (ACPCC) to implement their laboratory information management system (LIMS) to optimise and future-proof ACPCC’s laboratory workflows.
Implementation will occur throughout 2024, across the pathology division of ACPCC in Melbourne and will improve ACPCC’s laboratory efficiency by more effectively managing the flow of samples and data. ACPCC was attracted to Cirdan’s LIMS due to its ability to swiftly collect high volumes of data while increasing the efficiency and reducing the time taken for patient diagnosis. The implementation of Cirdan‘s ULTRA LIMS will support ACPCC’s mission to eliminate cervical cancer in Australia by 2035.
“We are delighted to work with ACPCC – a global leader in the prevention of cervical cancer -and support their tremendous work in Australia and in the wider world.”
Hugh Cormican, CEO, Cirdan
“The introduction of the new Cirdan LIMS will allow us to continue to build our versatility whilst maintaining our high-quality approach to reporting patients pathology results.”
Associate Professor Dave Hawkes, Director Molecular Microbiology at ACPCC
The Bank of Ireland Kernel Capital Growth Fund (NI) was designed to help SMEs in Northern Ireland to accelerate their growth. Invest Northern Ireland has committed £15 million of funding to this fund which is part financed by the European Regional Development Fund under the EU Investment for Growth and Jobs Programme 2014-2020.
